Aerodigestive tract invasion by well-differentiated thyroid carcinoma: Diagnosis, management, prognosis, and biology

Laryngoscope

Volumn 116, Issue 1, 2006, Pages 1-11

  McCaffrey, Judith Czaja ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CELL ADHESION MOLECULE; UVOMORULIN; CADHERIN; TUMOR MARKER;

ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RESPIRATORY TRACT CANCER; THYROID CARCINOMA; TRACHEA CARCINOMA; ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS TUMOR; FEMALE; LARYNX TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; THYROID TUMOR; THYROIDECTOMY; TRACHEA TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CADHERINS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED; TRACHEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645222614     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MLG.0000200428.26975.86     Document Type: Article

References (72)

1. Silliphant WM, Levitin MS. Thyroid carcinoma and death: a clinicopathological study of 193 autopsies. Cancer 1964;17:513-525.
2. McConahey WM, Hay ID, Woolner LB et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986;61:978-996.
3. Batsakis JG. Laryngeal involvement by thyroid disease. Ann Otol Rhinol Laryngol 1987;96:718-719.
4. Tollefson HD, Hutter R. Papillary carcinoma of the thyroid: a clinical and pathological study of 70 fatal cases. Cancer 1964;17:1035-1044.
5. Carter N, Milroy CM. Thyroid carcinoma causing fatal laryngeal occlusion. J Laryngol Otol 1996;110:1176-1178.
6. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. II. Value of prophylactic lymph node excision. Cancer 1970;26:1061-1064.
7. Noguchi M, Kinami S, Kinoshita K et al. Risk of bilateral cervical lymph node metastases in papillary thyroid cancer. J Surg Oncol 1993;52:155-159.
8. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003;3:17.
9. Campbell RJ, Pignatelli M. Molecular histology in the study of solid tumours. Mol Pathol 2002;55:80-82.
10. Ito Y, Yoshida H, Tomoda C et al. Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. Thyroid 2004;14:13-18.
11. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999;59:467-473.
12. Kusunoki T, Nishida S, Kimoto-Kinoshita S, et al. Type IV collagenase and immunostaining of type IV collagen in human thyroid tumors. Auris Nasus Larynx 2000;27:161-165.
13. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209-218.
14. Zedenius J, Stahle-Backdahl M, Enberg U, et al. Stromal fibroblasts adjacent to invasive thyroid tumors: expression of gelatinase A but not stromelysin 3 mRNA. World J Surg 1996;20:101-106.
15. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-2060.
16. Nomura H, Fujimoto N, Seiki M, et al. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996;69:9-16.
17. Demeure MJ, Damsky CH, Elfman F, et al. Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases. World J Surg 1992;16:770-776.
18. Kusunoki T, Nishida S, Kimoto-Kinoshita S, et al. Type IV collagen, type IV collagenase activity and ability of cell proliferation in human thyroid tumours. Asian J Surg 2002;25:304-308.
19. Higgins JM, Mandlebrot DA, Shaw SK, et al. Direct and regulated interaction of integrin alphaEbeta7 with E-cadherin. J Cell Biol 1998;140:197-210.
20. Machado JC, Soares P, Carneiro F, et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999;79:459-465.
21. Carneiro F, Machado JC, Seruca R, Sobrinho-Simoes M. E-cadherin changes in gastric carcinoma. Histopathology 1999;35:477-478.
22. Machado J, Carneiro F, Sobrinho-Simoes M. E-cadherin mutations in gastric carcinoma. J Pathol 2000;191:466-468.
23. Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001;20:1525-1528.
24. Huang SH, Wu JC, Chang KJ, et al. Distribution of the cadherin-catenin complex in normal human thyroid epithelium and a thyroid carcinoma cell line. J Cell Biochem 1998;70:330-337.
25. Naito A, Iwase H, Kuzushima T, et al. Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol 2001;76:176-180.
26. Rocha AS, Soares P, Seruca R, et al. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. J Pathol 2001;194:358-366.
27. Scheumman GF, Hoang-Vu C, Cetin Y, et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab 1995;80:2168-2172.
28. Serini G, Trusolino L, Saggiorato E, et al. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst 1996;88:442-449.
29. Rocha AS, Soares P, Fonseca E, et al. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 2003;42:580-587.
30. Sulzer MA, Leers MP, van Noord JA, et al. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 1998;157:1319-1323.
31. von Wasielewski R, Rhein A, Werner M, et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997;57:2501-2507.
32. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168.
33. Czaja JM, McCaffrey TV. The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:484-490.
34. Nagafuchi A, Takeichi M. Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1989;1:37-44.
35. Ballantyne AJ. Resections of the upper aerodigestive tract for locally invasive thyroid cancer. Am J Surg 1994;168:636-639.
36. Bayles SW, Kingdom TT, Carlson GW. Management of thyroid carcinoma invading the aerodigestive tract. Laryngoscope 1998;108:1402-1407.
37. Fujimoto Y, Obara T, Ito Y, et al. Aggressive surgical approach for locally invasive papillary carcinoma of the thyroid in patients over forty-five years of age. Surgery 1986;100:1098-1107.
38. Hefer T, Joachims HZ, Eitan A, et al. Highly invasive papillary thyroid carcinoma. J Laryngol Otol 1994;108:889-891.
39. Machens A, Hinze R, Dralle H. Surgery on the cervicovisceral axis for invasive thyroid cancer. Langenbecks Arch Surg 2001;386:318-323.
40. Nakao K, Miyata M, Izukura M, et al. Radical operation for thyroid carcinoma invading the trachea. Arch Surg 1984;119:1046-1049.
41. Grillo HC, Zannini P. Resectional management of airway invasion by thyroid carcinoma. Ann Thorac Surg 1986;42:287-298.
42. Grillo HC, Suen HC, Mathisen DJ, Wain JC. Resectional management of thyroid carcinoma invading the airway. Ann Thorac Surg 1992;54:3-10.
43. Melliere DJ, Ben Yahia NE, Becquemin JP, et al. Thyroid carcinoma with tracheal or esophageal involvement: limited or maximal surgery? Surgery 1993;113:166-172.
44. Musholt TJ, Musholt PB, Behrend M, et al. Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon. Surgery 1999;126:1078-1087.
45. Nishida T, Nakao K, Hamaji M. Differentiated thyroid carcinoma with airway invasion: indication for tracheal resection based on the extent of cancer invasion. J Thorac Cardiovasc Surg 1997;114:84-92.
46. Yang CC, Lee CH, Wang LS, et al. Resectional treatment for thyroid cancer with tracheal invasion: a long-term follow-up study. Arch Surg 2000;135:704-707.
47. Park CS, Suh KW, Min JS. Cartilage-shaving procedure for the control of tracheal cartilage invasion by thyroid carcinoma. Head Neck 1993;15:289-291.
48. Zannini P, Melloni G. Surgical management of thyroid cancer invading the trachea. Chest Surg Clin N Am 1996;6:777-790.
49. Hammoud ZT, Mathisen DJ. Surgical management of thyroid carcinoma invading the trachea. Chest Surg Clin N Am 2003;13:359-367.
50. Ozaki O, Sugino K, Mimura T, Ito K. Surgery for patients with thyroid carcinoma invading the trachea: circumferential sleeve resection followed by end-to-end anastomosis. Surgery 1995;117:268-271.
51. Donnelly MJ, Considine N, McShane DP. Upper airway invasion by well-differentiated thyroid carcinoma. J Laryngol Otol 1993;107:752-754.
52. Donnelly MJ, Timon CI, McShane DP. The role of total laryngectomy in the management of intraluminal upper airway invasion by well-differentiated thyroid carcinoma. Ear Nose Throat J 1994;73:659-662.
53. Cody HS III, Shah JP. Locally invasive, well-differentiated thyroid cancer. 22 years' experience at Memorial Sloan-Kettering Cancer Center. Am J Surg 1981;142:480-483.
54. Breaux GP Jr, Guillamondegui OM. Treatment of locally invasive carcinoma of the thyroid: how radical? Am J Surg 1980;140:514-517.
55. Kowalski LP, Filho JG. Results of the treatment of locally invasive thyroid carcinoma. Head Neck 2002;24:340-344.
56. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095.
57. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-1058.
58. Powers PA, Dinauer CA, Tuttle RM, Francis GL. The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. J Pediatr Endocrinol Metab 2004;17:339-343.
59. Kim KH, Sung MW, Chang KH, Kang BS. Therapeutic dilemmas in the management of thyroid cancer with laryngotracheal involvement. Otolaryngol Head Neck Surg 2000;122:763-767.
60. Shin DH, Mark EJ, Suen HC, Grillo HC. Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection. Hum Pathol 1993;24:866-870.
61. Friedman M, Toriumi DM, Owens R, Grybauskas VT. Experience with the sternocleidomastoid myoperiosteal flap for reconstruction of subglottic and tracheal defects: modification of technique and report of long-term results. Laryngoscope 1988;98:1003-1011.
62. Friedman M, Mayer AD. Laryngotracheal reconstruction in adults with the sternocleidomastoid myoperiosteal flap. Ann Otol Rhinol Laryngol 1992;101:897-908.
63. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996;77:172-180.
64. O'Connell ME, A'Hern RP, Harmer CL. Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. Eur J Cancer 1994;6:733-739.
65. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: thyroid carcinoma. In: Sherman S, ed. NCCN Practice Guidelines in Oncology . Jenkintown, PA: National Comprehensive Cancer Network, 2004.
66. Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am 1995;24:711-760.
67. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318-4323.
68. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995;24:841-863.
69. Baskin HJ. Effect of postoperative 131I treatment on thyroglobulin measurements in the follow-up of patients with thyroid cancer. Thyroid 1994;4:239-242.
70. Baskin HJ. Thyroglobulin: a clinical review. Endocrine Pract 1995;1:365-367.
71. Girelli ME, Busnardo B, Amerio R, et al. Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: results in 291 patients with thyroid cancer. Eur J Nucl Med 1986;11:333-335.
72. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 2000;30:107-114.